CD274 and non-small cell lung carcinoma: More recently, pembrolizumab monotherapy for patients with a high level of tumor programmed cell death ligand-1 (PD-L1) expression ≥1% became the standard first-line therapy for advanced NSCLC without treatable driver mutations (1–3).